In 2020, the WFH Humanitarian Aid Program donated over 5.5 million IUs of factor concentrates, and over 100,000 mg of non-factor replacement therapy, to Pakistan. These treatments have allowed people with bleeding disorders (PWBD) in the country to enjoy a better quality of life. In many cases, these donations have saved lives—as is the case of Shahveer, a one-year-old boy with severe hemophilia A.
Shahveer was born in Lahore with a cephalohematoma which required a blood transfusion, and which only subsided after three months of care. He was just a few months old when it was noticed that he bruised easily on his chest and arms. At seven months old, he was admitted to a private hospital with an intracranial bleed, and a lab analysis diagnosed him with hemophilia. As clotting factor concentrate (CFC) wasn’t available in this private hospital, he was given cryoprecipitate, and responded well to the treatment.
Only three months later, Shahveer was admitted to Lahore Hemophilia Treatment Centre (HTC), and he was found to have inhibitors. It was at this point that he was treated by Shahla Sohail, MD, the principal treater at the HTC, and received his first dose of non-factor replacement therapy donated by the WFH Humanitarian Aid Program. For this prophylactic therapy, he was initially given a loading dose of one vial a week for a month, and he was then put on a maintenance dose of two vials a month. The non-factor replacement therapy has been transformative for Shahveer. He has not had a bleed since starting treatment, is able to walk and talk like other boys his age, and now has a fair chance at a normal life.
To find out more about the WFH Humanitarian Aid Program, please click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.